LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "roxadustat" as a keyword



Roxadustat versus placebo for patients with lower‐risk myelodysplastic syndrome: MATTERHORN phase 3, double‐blind, randomized controlled trial

Sign Up to like & get
recommendations! Published in 2024 at "American Journal of Hematology"

DOI: 10.1002/ajh.27410

Abstract: In patients with lower‐risk myelodysplastic syndromes/neoplasms (MDS), response to first‐line therapy is limited and transient. The MATTERHORN randomized, double‐blind, phase 3 trial evaluated roxadustat versus placebo for patients with transfusion‐dependent, lower‐risk MDS. Eligible patients had… read more here.

Keywords: roxadustat; risk; patients lower; lower risk ... See more keywords

Effect of Roxadustat on the Pharmacokinetics of Simvastatin, Rosuvastatin, and Atorvastatin in Healthy Subjects: Results From 3 Phase 1, Open‐Label, 1‐Sequence, Crossover Studies

Sign Up to like & get
recommendations! Published in 2022 at "Clinical Pharmacology in Drug Development"

DOI: 10.1002/cpdd.1076

Abstract: Roxadustat inhibits breast cancer resistance protein and organic anion transporting polypeptide 1B1, which can affect coadministered statin concentrations. Three open‐label, 1‐sequence crossover phase 1 studies in healthy subjects were conducted to assess effects from steady‐state… read more here.

Keywords: roxadustat; label sequence; sequence crossover; atorvastatin ... See more keywords

Evaluation of Food and Spherical Carbon Adsorbent Effects on the Pharmacokinetics of Roxadustat in Healthy Nonelderly Adult Male Japanese Subjects

Sign Up to like & get
recommendations! Published in 2019 at "Clinical Pharmacology in Drug Development"

DOI: 10.1002/cpdd.597

Abstract: Roxadustat is a hypoxia‐inducible factor prolyl hydroxylase inhibitor in late‐stage clinical development for the treatment of anemia in chronic kidney disease. Spherical carbon adsorbent (SCA) is used in patients with chronic kidney disease and has… read more here.

Keywords: pharmacokinetics roxadustat; time; drug; effect ... See more keywords

Long-Term Excretion of Roxadustat in Urine.

Sign Up to like & get
recommendations! Published in 2024 at "Drug testing and analysis"

DOI: 10.1002/dta.3813

Abstract: Roxadustat (FG-4592), an orally active hypoxia-inducible factor prolyl hydroxylase stabilizer, has been shown to enhance erythropoiesis by increasing endogenous erythropoietin. It is indicated for the treatment of anemia and chronic kidney disease and is approved… read more here.

Keywords: roxadustat; excretion roxadustat; long term; excretion ... See more keywords
Photo from wikipedia

The efficacy and safety of roxadustat treatment for anemia in patients with kidney disease: a meta-analysis and systematic review

Sign Up to like & get
recommendations! Published in 2021 at "International Urology and Nephrology"

DOI: 10.1007/s11255-020-02693-7

Abstract: Background Anemia is a common complication for patients with kidney disease. Roxadustat is an oral hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor (PHI), which is a newly approved oral drug for anemia. We performed this study… read more here.

Keywords: anemia; analysis; safety; disease ... See more keywords

Esterification promotes the intracellular accumulation of roxadustat, an activator of hypoxia-inducible factors, to extend its effective duration.

Sign Up to like & get
recommendations! Published in 2022 at "Biochemical pharmacology"

DOI: 10.1016/j.bcp.2022.114939

Abstract: Kidney injury often causes anemia due to a lack of production of the erythroid growth factor erythropoietin (EPO) in the kidneys. Roxadustat is one of the first oral medicines inducing EPO production in patients with… read more here.

Keywords: hypoxia inducible; effective duration; esterification; inducible factors ... See more keywords

Roxadustat treatment for anemia in peritoneal dialysis patients: A randomized controlled trial.

Sign Up to like & get
recommendations! Published in 2021 at "Journal of the Formosan Medical Association = Taiwan yi zhi"

DOI: 10.1016/j.jfma.2021.06.004

Abstract: BACKGROUND/PURPOSE Roxadustat, a first-in-class hypoxia-inducible factor prolyl hydroxylase inhibitor, promotes erythropoiesis and regulates iron metabolism. This study investigated the efficacy and safety of roxadustat in Chinese patients with anemia on peritoneal dialysis (PD). METHODS One… read more here.

Keywords: week; trial; anemia peritoneal; treatment ... See more keywords

Effect of roxadustat on lowering blood lipids in peritoneal dialysis patients with anemia

Sign Up to like & get
recommendations! Published in 2025 at "Renal Failure"

DOI: 10.1080/0886022x.2025.2460726

Abstract: Abstract Objectives To observe the effect of roxadustat on lowering blood lipids in peritoneal dialysis (PD) patients beyond treating anemia. Methods In a prospective, multicenter clinical study, we randomly assigned (in a 1:1 ratio) 100… read more here.

Keywords: roxadustat lowering; roxadustat; lowering blood; effect roxadustat ... See more keywords
Photo from wikipedia

Therapeutic Potential of the Prolyl Hydroxylase Inhibitor Roxadustat in a Mouse Hindlimb Lymphedema Model.

Sign Up to like & get
recommendations! Published in 2023 at "Lymphatic research and biology"

DOI: 10.1089/lrb.2022.0071

Abstract: Background: Lymphedema is an intractable disease with no curative treatment available. Conservative treatment is the mainstay, and new drug treatment options are strongly needed. The purpose of this study was to investigate the effect of… read more here.

Keywords: roxadustat; lymphedema; group; hindlimb lymphedema ... See more keywords

FC 071ENHANCED DEGRADATION OF 3-HYDROXY-3-METHYLGLUTARYL COENZYME A REDUCTASE (HMGCR) MAY CONTRIBUTE TO THE LOWERING OF LDL CHOLESTEROL SEEN WITH ROXADUSTAT IN CHRONIC KIDNEY DISEASE PATIENTS WITH ANEMIA

Sign Up to like & get
recommendations! Published in 2021 at "Nephrology Dialysis Transplantation"

DOI: 10.1093/ndt/gfab118.001

Abstract: Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor approved in China and Japan for the treatment of anemia in patients with chronic kidney disease (CKD). In Phase 3 clinical studies, roxadustat was shown… read more here.

Keywords: roxadustat; cholesterol; hmgcr; effect ... See more keywords

#1948 Transcriptome analysis of the effect of roxadustat on osteoclasts

Sign Up to like & get
recommendations! Published in 2024 at "Nephrology Dialysis Transplantation"

DOI: 10.1093/ndt/gfae069.1450

Abstract: In recent years, hypoxia-inducing factor prolyl hydroxylase inhibitors (HIF-PHIs) have been widely used in the treatment of renal anemia, bringing a revolutionary breakthrough in the treatment of anemia in CKD patients. However, HIF-PHIs acts on… read more here.

Keywords: roxadustat; analysis; osteoclast differentiation; effect roxadustat ... See more keywords